A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression

Journal of Clinical Psychiatry

Volumn 72, Issue 10, 2011, Pages 1405-1412

  Barbee, James G ^a   Thompson, Thomas R ^b   Jamhour, Nowal J ^a   Stewart, Jonathan W ^c   Conrad, Erich J ^a   Reimherr, Frederick W ^d   Thompson, Peter M ^e   Shelton, Richard C ^f  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e Mays Cancer Center at UT Health San Antonio   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; LAMOTRIGINE; PAROXETINE; PLACEBO; ZOLPIDEM;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; INFORMATION PROCESSING; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; PNEUMONIA; POST HOC ANALYSIS; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SUICIDAL BEHAVIOR; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 80054920298     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05355gre     Document Type: Article

References (33)

1. Calabrese JR, Bowden CL, Sachs G, et al.; for the Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64(9):1013-1024. doi:10.408/JCP.v64n0906 PubMed (Pubitemid 37158246)
2. Bowden CL, Calabrese JR, Sachs G, et al.; for the Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392-400. doi:10.101/archpsyc.60.4.392 PubMed (Pubitemid 36403000)
3. Calabrese JR, Bowden CL, Sachs GS, et al. Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999;60(2):79-88. PubMed (Pubitemid 29104383)
4. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009; 194(1):4-9. doi:10.192/bjp.bp.107.048504 PubMed
5. GlaxoSmithKline. An eight-week, multicenter, double-blind, randomized, fixed-dose evaluation of the efficacy and safety of lamotrigine (200 mg/d), desipramine (200 mg/d), and placebo in outpatients with unipolar depression (result summary for study SCAA2011 [105-613]). http://download.gsk- clinicalstudyregister.com/files/1666.pdf. Verified October 7, 2010.
6. GlaxoSmithKline. A randomized, multicenter, double-blind, placebocontrolled, fixed-dose, 7-week evaluation of the efficacy and safety of lamotrigine in patients with major depression (result summary for study SCA20022). http://download.gsk-clinicalstudyregister.com/files/ 1661.pdf. Verified October 7, 2010.
7. GlaxoSmithKline. A randomized, multicenter, double-blind, placebocontrolled, fixed-dose, 7-week evaluation of the efficacy and safety of lamotrigine in treatment of a major depressive episode in unipolar depressed patients (result summary for study SCA20025). http://download. gsk-clinicalstudyregister.com/files/1663.pdf. Verified October 7, 2010.
8. Normann C, Hummel B, Schärer LO, et al. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry. 2002;63(4):337-344. PubMed (Pubitemid 34456362)
9. Obrocea GV, Dunn RM, Frye MA, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry. 2002;51(3):253-260. doi:10.1016/S06-323(01)01206-9 PubMed (Pubitemid 34142637)
10. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebocontrolled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003;64(4):403-407. doi:10.408/JCP.v64n0407 PubMed (Pubitemid 36547282)
11. Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry. 2002;63(8):737-741. PubMed
12. Rocha FL, Hara C. Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol. 2003;18(2):97-99. doi:10.1097/04850-203030-06 PubMed (Pubitemid 36343979)
13. Gutierrez RL, McKercher RM, Galea J, et al. Lamotrigine augmentation strategy for patients with treatment-resistant depression. CNS Spectr. 2005;10(10):800-805. PubMed (Pubitemid 41534642)
14. Gabriel A. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study. Depress Anxiety. 2006;23(8):485-488. doi:10.102/da.2021 PubMed (Pubitemid 44917668)
15. Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry. 2008;10(3):187-190. doi:10.408/PC.v10n0302 PubMed (Pubitemid 351879952)
16. Hamilton M. A rating scale for depression. J Neursurg Psychiatry. 1960; 23(1):56-62. doi:10.136/jnp.23.1.56
17. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. PubMed
18. Mundt JC, Kobak KA, Taylor LV, et al. Administration of the Hamilton Depression Rating Scale using interactive voice response technology. MD Comput. 1998;15(1):31-39. PubMed (Pubitemid 128406314)
19. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):10-17. PubMed
20. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13): 23-29. PubMed (Pubitemid 28011969)
21. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382 PubMed (Pubitemid 9136500)
22. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
23. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385-401. doi:10.17/01462167010306
24. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36), 1: Conceptual framework and item selection. Med Care. 1992;30(6):473-483. doi:10.1097/05650-192060-02 PubMed
25. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3):89-95. doi:10.1097/04850-1960603-015 PubMed (Pubitemid 26373761)
26. Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, eds. Issues in Pain Measurement. New York, NY: Raven Press; 1989:391-403.
27. Smith TL, Klein MH, Benjamin LS. Validation of the Wisconsin Personality Disorders Inventory-IV with the SCID-II. J Pers Disord. 2003;17(3):173-187. doi:10.1521/pedi.17.3.173.2150 PubMed (Pubitemid 36741559)
28. Wender PH. Wender AQCC (Adult Questionnaire-Childhood Characteristics) Scale. Psychopharmacol Bull. 1995;21:927-928.
29. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1): 131-134. doi:10.176/api.ajp.158.1.131 PubMed (Pubitemid 32047260)
30. Nemeroff CB. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res. 2007;41(3-4): 189-206. doi:10.1016/j.jpsychires.206.05.08 PubMed (Pubitemid 44854991)
31. Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry. 2003;53(8):640-648. doi:10.1016/S06- 323(02)01670-0 PubMed (Pubitemid 39658480)
32. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853. doi:10.408/JCP.v68n0604 PubMed (Pubitemid 47015482)
33. Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005;25(4):336-341. (Pubitemid 41060253)